Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Knoll Considering Segard Plans; Sepsis Study Shows Small Mortality Benefit

Executive Summary

Knoll is considering the next step for its TNF inhibitor Segard, after one of two pivotal trials for sepsis showed a modest mortality benefit.
Advertisement

Related Content

Sepsis Pipeline Could Be Resuscitated With Narrower Trials, Researchers Propose
Abbott Projects Synthroid Double-Digit Growth Despite Early-2002 Phase-Down
Abbott Projects Synthroid Double-Digit Growth Despite Early-2002 Phase-Down
Knoll Takeover Value Hinges On Outlook For D2E7 Rheumatoid Arthritis Agent
Knoll Takeover Value Hinges On Outlook For D2E7 Rheumatoid Arthritis Agent
Lilly Sepsis Trial Prompts Biotech-Style Jump In Second Quarter
Lilly Sepsis Trial Prompts Biotech-Style Jump In Second Quarter
Advertisement
UsernamePublicRestriction

Register

PS036303

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel